|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bowtell DD: The genesis and evolution of
high-grade serous ovarian cancer. Nat Rev Cancer. 10:803–808. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bast RC Jr, Hennessy B and Mills GB: The
biology of ovarian cancer: New opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rechsteiner M, Zimmermann AK, Wild PJ,
Caduff R, von Teichman A, Fink D, Moch H and Noske A: TP53
mutations are common in all subtypes of epithelial ovarian cancer
and occur concomitantly with KRAS mutations in the mucinous type.
Exp Mol Pathol. 95:235–241. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Friedlander LT, Hussani H, Cullinan MP,
Seymour GJ, De Silva RK, De Silva H, Cameron C and Rich AM: VEGF
and VEGFR2 in dentigerous cysts associated with impacted third
molars. Pathology. 47:446–451. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zabouo G, Imbert AM, Jacquemier J, Finetti
P, Moreau T, Esterni B, Birnbaum D, Bertucci F and Chabannon C:
CD146 expression is associated with a poor prognosis in human
breast tumors and with enhanced motility in breast cancer cell
lines. Breast Cancer Res. 11:R12009. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shih IM: The role of CDl46 (Mel-CAM) in
biology and pathology. J Pathol. 189:4–11. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yan X, Lin Y, Yang D, Shen Y, Yuan M,
Zhang Z, Li P, Xia H, Li L, Luo D, et al: A novel anti-CDl46
monoclonal antibody, AA98, inhibits angiogenesis and tumor growth.
Blood. 102:184–191. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu GJ, Varma VA, Wu MW, Wang SW, Qu P,
Yang H, Petros JA, Lim SD and Amin MB: Expression of a human cell
adhesion molecule, MUCl8, in prostate cancer cell lines and
tissues. Prostate. 48:305–315. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bardin N, Anfosso F, Massé JM, Cramer E,
Sabatier F, Le Bivic A, Sampol J and Dignat-George F:
Identification of CDl46 a component of the endothelial junction
involved in the control of cell-cell cohesion. Blood. 98:3677–3684.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kang Y, Wang F, Feng J, Yang D, Yang X and
Yan X: Knockdown of CDl46 reduces the migration and proliferation
of human endothelial cells. Cell Res. 16:313–318. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Campbell NE, Kellenberger L, Greenaway J,
Moorehead RA, Linnerth-Petrik NM and Petrik J: Extracellular matrix
proteins and tumor angiogenesis. J Oncol. 2010:5869052010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vainio O, Dunon D, Aïssi F, Dangy JP,
McNagny KM and Imhof BA: HEMCAM, an adhesion molecule expressed by
c-kit+ hemopoietic progenitors. J Cell Biol. 135:1655–1668. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bowen MA, Patel DD, Li X, Modrell B,
Malacko AR, Wang WC, Marquardt H, Neubauer M, Pesando JM, Francke
U, et al: Cloning, mapping, and characterization of activated
leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med.
181:2213–2220. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Anfosso F, Bardin N, Francès V, Vivier E,
Camoin-Jau L, Sampol J and Dignat-George F: Activation of human
endothelial cells via S-endo 1 antigen (CDl46) stimulates the
tyrosine phosphorylation of focal adhesion kinase p125(FAK). J Biol
Chem. 273:26852–26856. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bardin N, Francès V, Combes V, Sampol J
and Dignat-George F: CDl46: Biosynthesis and production of a
soluble form in human cultured endothelial cells. FEBS Lett.
421:12–14. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kang Y, Wang F, Feng J, Yang D, Yang X and
Yan X: Knockdown of CDl46 reduces the migration and proliferation
of human endothelial cells. Cell Res. 16:313–318. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schrage A, Loddenkemper C, Erben U, Lauer
U, Hausdorf G, Jungblut PR, Johnson J, Knolle PA, Zeitz M, Hamann A
and Klugewitz K: Murine CDl46 is widely expressed on endothelial
cells and is recognized by the monoclonal antibody ME-9F1.
Histochem Cell Biol. 129:441–451. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bardin N, Blot-Chabaud M, Despoix N, Kebir
A, Harhouri K, Arsanto JP, Espinosa L, Perrin P, Robert S, Vely F,
et al: CDl46 and its soluble form regulate monocyte
transendothelial migration. Arterioscler Thromb Vasc Biol.
29:746–753. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng C, Qiu Y, Zeng Q, Zhang Y, Lu D,
Yang D, Feng J and Yan X: Endothelial CDl46 is required for in
vitro tumor-induced angiogenesis: The role of a disulfide bond in
signaling and dimerization. Int J Biochem Cell Bio. 41:2163–2172.
2009. View Article : Google Scholar
|
|
21
|
Satyamoorthy K, Muyrers J, Meier F, Patel
D and Herlyn M: Mel-CAM-specific genetic suppressor elements
inhibit melanoma growth and invasion through loss of gap junctional
communication. Oneogene. 20:4676–4684. 2001. View Article : Google Scholar
|
|
22
|
Hollingsworth HC, Kohn EC, Steinberg SM,
Rothenberg ML and Merino MJ: Tumor angiogenesis in advanced stage
ovarian carcinoma. Am J Pathol. 147:33–41. 1995.PubMed/NCBI
|
|
23
|
Gasparini G, Bonoldi E, Viale G, Verderio
P, Boracchi P, Panizzoni GA, Radaelli U, Di Bacco A, Guglielmi RB
and Bevilacqua P: Prognostic and predictive value of tumor
angiogenesis in ovarian carcinomas. Int J Cancer. 69:205–211. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Orre M, Lotfi-Miri M, Mamers P and Rogers
PA: Increased microvessel density in mucinous compared with
malignant serous and benign tumours of the ovary. Br J Cancer.
77:2204–2209. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nakanishi Y, Kodama J, Yoshinouchi M,
Tokumo K, Kamimura S, Okuda H and Kudo T: The expression of
vascular endothelial growth factor and transforming growth
factor-beta associates with angiogenesis in epithelial ovarian
cancer. Int J Gynecol Pathol. 16:256–262. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamamoto S, Konishi I, Mandai M, Kuroda H,
Komatsu T, Nanbu K, Sakahara H and Mori T: Expression of vascular
endothelial growth factor (VEGF) in epithelial ovarian neoplasms:
Correlation with clinicopathology and patient survival, and
analysis of serum VEGF levels. Br J Cancer. 76:1221–1227. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Komatsu H, Oishi T, Itamochi H, Shimada M,
Sato S, Chikumi J, Sato S, Nonaka M, Sawada M, Wakahara M, et al:
Serum vascular endothelial growth factor-A as a prognostic
biomarker for epithelial ovarian cancer. Int J Gynecol Cancer.
27:1325–1332. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jouve N, Bachelier R, Despoix N, Blin MG,
Matinzadeh MK, Poitevin S, Aurrand-Lions M, Fallague K, Bardin N,
Blot-Chabaud M, et al: CD146 mediates VEGF-induced melanoma cell
extravasation through FAK activation. Int J Cancer. 137:50–60.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang W, Yang ZL, Liu JQ, Jiang S and Miao
XY: Identification of CD146 expression, angiogenesis, and
lymphangiogenesis as progression, metastasis, and poor-prognosis
related markers for gallbladder adenocarcinoma. Tumour Biol.
33:173–182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang T, Zhuang J, Duan H, Luo Y, Zeng Q,
Fan K, Yan H, Lu D, Ye Z, Hao J, et al: CD146 is a coreceptor for
VEGFR-2 in tumor angiogenesis. Blood. 120:2330–2339. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Aldovini D, Demichelis F, Doglioni C, Di
Vizio D, Galligioni E, Brugnara S, Zeni B, Griso C, Pegoraro C,
Zannoni M, et al: M-CAM expression as marker of poor prognosis in
epithelial ovarian cancer. Int J Cancer. 119:1920–1926. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Weddell JC and Imoukhuede PI: Quantitative
characterization of cellular membrane-receptor heterogeneity
through statistical and computational modeling. PLoS One.
9:e972712014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kornbrot D: Statistical software for
microcomputers: SigmaPlot 2000 and SigmaStat2. Br J Math Stat
Psychol. 53:335–337. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu GJ, Wu MW, Wang SW, Liu Z, Qu P, Peng
Q, Yang H, Varma VA, Sun QC, Petros JA, et al: Isolation and
characterization of the major form of human MUC18 cDNA gene and
correlation of MUC18 overexpression in prostate cancer cell lines
and tissues with malignant progression. Gene. 279:17–31. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu WF, Ji SR, Sun JJ, Zhang Y, Liu ZY,
Liang AB and Zeng HZ: CD146 expression correlates with
epithelial-mesenchymal transition markers and a poor prognosis in
gastric cancer. Int J Mol Sci. 13:6399–6406. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Oka S, Uramoto H, Chikaishi Y and Tanaka
F: The expression of CD146 predicts a poor overall survival in
patients with adenocarcinoma of the lung. Anticancer Res.
32:861–864. 2012.PubMed/NCBI
|
|
38
|
Sato A, Torii I, Okamura Y, Yamamoto T,
Nishigami T, Kataoka TR, Song M, Hasegawa S, Nakano T, Kamei T and
Tsujimura T: Immunocytochemistry of CD146 is useful to discriminate
between malignant pleural mesothelioma and reactive mesothelium.
Mod Pathol. 23:1458–1466. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kristiansen G, Yu Y, Schlüns K, Sers C,
Dietel M and Petersen I: Expression of the cell adhesion molecule
CD146/MCAM in non-small cell lung cancer. Anal Cell Pathol.
25:77–81. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen W, Zhang HL, Jiang YG, Li JH, Liu BL
and Sun MY: Inhibition of CD146 gene expression via RNA
interference reduces in vitro perineural invasion on ACC-M Cell. J
Oral Pathol Med. 38:198–205. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zeng Q, Li W, Lu D, Wu Z, Duan H, Luo Y,
Feng J, Yang D, Fu L and Yan X: CD146, an epithelial-mesenchymal
transition inducer, is associated with triple-negative breast
cancer. Proc Natl Acad Sci USA. 109:1127–1132. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
American Cancer Society. Cancer Facts
& Figures 2012 Atlanta: American Cancer Society; 2012
|
|
43
|
Takahashi Y, Kitadai Y, Bucana CD, Cleary
KR and Ellis LM: Expression of vascular endothelial growth factor
and its receptor, KDR, correlates with vascularity, metastasis, and
proliferation of human colon cancer. Cancer Res. 55:3964–3968.
1995.PubMed/NCBI
|
|
44
|
Lu Y, Xu Q, Zuo Y, Liu L, Liu S, Chen L,
Wang K, Lei Y, Zhao X and Li Y: Isoprenaline/β2-AR activates
Plexin-A1/VEGFR2 signals via VEGF secretion in gastric cancer cells
to promote tumor angiogenesis. BMC Cancer. 17:8752017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Paley PJ, Staskus KA, Gebhard K, Mohanraj
D, Twiggs LB, Carson LF and Ramakrishnan S: Vascular endothelial
growth factor expression in early stage ovarian carcinoma. Cancer.
80:98–106. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shen GH, Ghazizadeh M, Kawanami O, Shimizu
H, Jin E, Araki T and Sugisaki Y: Prognostic significance of
vascular endothelial growth factor expression in human ovarian
carcinoma. Br J Cancer. 83:196–203. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Premalata CS, Umadevi K, Shobha K,
Anurekha M and Krishnamoorthy L: Expression of VEGF-A in epithelial
ovarian cancer: Correlation with morphologic types, grade and
clinical stage. Gulf J Oncolog. 1:49–54. 2016.PubMed/NCBI
|
|
48
|
Duncan TJ, Al-Attar A, Rolland P, Scott
IV, Deen S, Liu DT, Spendlove I and Durrant LG: Vascular
endothelial growth factor expression in ovarian cancer: A model for
targeted use of novel therapies? Clin Cancer Res. 14:3030–3035.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yan H, Zhang C, Wang Z, Tu T, Duan H, Luo
Y, Feng J, Liu F and Yan X: CD146 is required for VEGF-C-induced
lymphatic sprouting during lymphangiogenesis. Sci Rep. 7:74422017.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Nodomi S, Umeda K, Saida S, Kinehara T,
Hamabata T, Daifu T, Kato I, Hiramatsu H, Watanabe KI, Kuwahara Y,
et al: CD146 is a novel marker for highly tumorigenic cells and a
potential therapeutic target in malignant rhabdoid tumor. Oncogene.
35:5317–5327. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tsiolakidou G, Koutroubakis IE, Tzardi M
and Kouroumalis EA: Increased expression of VEGF and CD146 in
patients with inflammatory bowel disease. Dig Liver Dis.
40:673–679. 2008. View Article : Google Scholar : PubMed/NCBI
|
